期刊文献+

甲状腺功能亢进对住院患者医院感染率的影响及干预措施研究 被引量:3

Effect of hyperthyroidism on nosocomial infection rate of patients and intervention measures
原文传递
导出
摘要 目的研究甲状腺功能亢进对住院患者医院感染发生情况的影响并探讨干预措施,为临床治疗提供参考依据。方法选取2012-2015年医院收治的215例甲亢患者为研究对象,配对选取同一时期的住院患者215例为对照组,比较两组患者的临床资料及院内感染率,并分析甲亢患者出现感染的危险因素。结果甲亢患者及对照组患者性别、年龄、并发症、BMI、血压、LVEF、血常规及血生化检查结果比较,差异无统计学意义;甲亢组22例患者出现感染,感染率10.23%;对照组7例患者发生感染,感染率3.26%,差异有统计学意义(P<0.05);合并心脏病、重型甲亢、LVEF≤45%、白细胞<4×10~9/L是发生感染的独立危险因素(P<0.05)。结论甲亢患者医院感染的发生率较高,且与多种因素有关,临床上应该采取综合措施全面干预。 OBJECTIVE To study the effect of hyperthyroidism on nosocomial infections of patients and the inter- vention measures, so as to provide references for clinical treatment. METHODS From Jan. 2012 to Dec. 2015, 215 patients with hyperthyroidism were chosen as study objects, and 215 patients without hyperthyroidism were cho- sen as control group. The clinical data and nosocomial infection rate were compared between the two groups, and the risk factors of infection in patients with hyperthyroidism were analyzed. RESULTS The gender, age, complica- tions, BMI, blood pressure, LVEF, results of blood routine and blood biochemistry had no significant difference between the two groups. The nosocomial infection rate of hyperthyroidism patients was 10.23 % (22/215), that of control group was 3.26 % (7/215), and the difference had significance(P〈0.05). Heart disease, severe hyperthy- roidism, LVEF≤ 45%, and WBC 〈 4× 109/L were independent risk factors for infections (P 〈 0. 05). CONCLUSION Patients with hyperthyroidism are vulnerable to nosocomlal infections, which is related to multiple factors, and thus requires comprehensive intervention measures in clinic.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2017年第8期1789-1791,1798,共4页 Chinese Journal of Nosocomiology
关键词 甲状腺功能亢进 医院感染 危险因素 Hyperthyroidism Nosocomial infection Risk factors
  • 相关文献

参考文献4

二级参考文献29

  • 1伍卫,刘品明,江山平,王景峰.大内科存在的价值与重要性[J].中华内科杂志,2004,43(9):645-646. 被引量:1
  • 2叶任髙,陆再英.内科学[M].北京:人民卫生出版社,2004:247-260.
  • 3中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志,2007,46(10):876-882. 被引量:835
  • 4李卉.甲状腺功能亢进症病证结合诊疗方法及疗效观察[D].北京:北京中医药大学,2012.
  • 5Paschke R, Niedziela M, Vaidya B, et al. 2012 European Thyroid Association Guidelines for the management of familial and persistant sporadic non-autoimmune hyperthyroidism caused by thyroid-stimulating hormone receptor germline mutations[J]. Eur Thyroid J, 2012,1:142-147.
  • 6Nwosu BU, Gourgiotis L, Gershengorn MC, et al. A novel activating mutation in transmembrane helix 6 of the thyrotropin receptor as cause of hereditary nonautoimmune hyperthyroidism[J]. Thyroid, 2006,16:505-512.
  • 7Alberti L, Proverbio MC, Costagliola S, et al. A novel germline mutation in the TSH receptor gene causes non-autoimmune autosomal dominant hyperthyroidism[J]. Eur J Endocrinol, 2001,145: 249-254.
  • 8Karges B, Krause G, Homoki J, et al. TSH receptor mutation V509A causes familial hyperthyroidism by release of interhelical constraints between transmembrane helices TMH3 and TMH5[J]. J Endocrinol, 2005,186:377-385.
  • 9Fuhrer D, Warner J, Sequeira M, et al. Novel TSHR germline mutation (Met463Val) masquerading as Graves′ disease in a large Welsh kindred with hyperthyroidism[J]. Thyroid, 2000,10:1035-1041.
  • 10Vaidya B, Campbell V, Tripp JH, et al. Premature birth and low birth weight associated with nonautoimmune hyperthyroidism due to an activating thyrotropin receptor gene mutation[J]. Clin Endocrinol (Oxf), 2004,60:711-718.

共引文献44

同被引文献20

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部